Junki Mizusawa

14PUBLICATIONS
85CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Pharmaceutical delivery technologiesPredictive and prognostic markersRadiation therapyEpidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jun 26, 2026
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.

|Jun 24, 2026
A multicenter randomized phase III trial of weekly cisplatin chemoradiotherapy versus radiotherapy in elderly patients with head and neck squamous cell carcinoma unfit for high-dose cisplatin: JCOG2405 (ELDER-WEEKLY).

|Jun 18, 2026
A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART).

|Feb 04, 2026
Adaptive Seamless Phase II/III Randomization Test Considering Treatment Group Selection Based on Short-Term Binary Outcomes.

Funato Sato, Kohei Uemura, Junki Mizusawa

|Jan 21, 2026
Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603.

Yukihide Kanemitsu, Yasuhiro Shimizu, Junki Mizusawa

|Jul 28, 2025
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.

Akihiro Ohba, Masato Ozaka, Junki Mizusawa

Pageof 3

Frequent Collaborators

5 joint publications

Hiroshi Katayama

4 joint publications

Yukihide Kanemitsu

3 joint publications

Naomi Kiyota

3 joint publications

Shunsuke Tsukamoto